Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) FCF Margin (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of FCF Margin data on record, last reported at 201.13% in Q4 2025.

  • For Q4 2025, FCF Margin rose 14518.0% year-over-year to 201.13%; the TTM value through Dec 2025 reached 275.42%, down 9181.0%, while the annual FY2025 figure was 276.24%, 9263.0% down from the prior year.
  • FCF Margin reached 201.13% in Q4 2025 per CCCC's latest filing, up from 280.58% in the prior quarter.
  • Across five years, FCF Margin topped out at 43.07% in Q2 2024 and bottomed at 1162.19% in Q4 2022.
  • Average FCF Margin over 5 years is 394.22%, with a median of 312.1% recorded in 2021.
  • Peak YoY movement for FCF Margin: plummeted -103379bps in 2022, then soared 69837bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 128.4% in 2021, then plummeted by -805bps to 1162.19% in 2022, then surged by 36bps to 741.06% in 2023, then skyrocketed by 53bps to 346.3% in 2024, then skyrocketed by 42bps to 201.13% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 201.13% in Q4 2025, 280.58% in Q3 2025, and 186.55% in Q2 2025.